MedPath

Phase I study of CMV specific CTL generated from third party for treatment of antiviral drug-resistant CMV infection after allogeneic stem cell transplantatio

Phase 1
Conditions
Antiviral drug-resistant CMV infection after allogeneic stem cell transplantation
Registration Number
JPRN-UMIN000015556
Lead Sponsor
agoya University Graduate School of Medicine, Department of Hematology and Oncology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
9
Inclusion Criteria

Not provided

Exclusion Criteria

1. Severe or uncontrollable bacterial, fungal,and viral (except CMV) infection 2. Uncontrollable GVHD 3. Uncontrollable heart failure 4. Psychoses 5.History of allergic reaction to albumin

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath